Dana Pharmaceutical Company
Dana Pharmaceutical Company is a Tabriz-based manufacturer of active pharmaceutical ingredients and finished medicines, listed on Iran Fara Bourse under ticker DDANA. Its operations cover antibiotic APIs, oral and sterile antibiotics, injectables, capsules, tablets and other dosage forms. The company matters to buyers, suppliers and investors monitoring Iranian pharmaceutical production and export-oriented drug manufacturing.
Market position
An Iran Fara Bourse-listed pharmaceutical manufacturer combining API production with finished-dose medicines, including antibiotic and sterile product lines.
Operations & footprint
Products and services
Dana Pharmaceutical Company manufactures active pharmaceutical ingredients and finished pharmaceutical products, with emphasis on antibiotic APIs, oral and sterile antibiotics, injectable vials, soft-gel capsules, hard capsules, tablets, oral suspensions, sterile drops, sterile water for injection, eye drops, cardiovascular products, gastrointestinal products, supplements, and selected biotechnology or pharmaceutical development categories.
Operations and assets
The company operates pharmaceutical manufacturing activities for APIs and finished dosage forms, spanning oral and sterile antibiotics, injectable vials, soft-gel and hard capsules, tablets, suspensions, sterile drops, sterile water for injection and eye drops.
Geographic footprint
Based in Tabriz, East Azerbaijan Province, Iran. Export activity is a stated strategic focus.
Commercial and investment relevance
Dana Pharmaceutical is relevant for investors assessing Iran's listed pharmaceutical sector, antibiotic API localization, sterile-drug capacity, export potential, healthcare supply resilience, and the economics of large drug manufacturers outside Tehran. It can support analysis of medicine shortages, API dependence, pricing regulation, distributor receivables, GMP standards, and foreign-currency exposure. Due diligence should review updated Codal disclosures, production-line utilization, API sourcing, export registrations, product mix, regulatory compliance, quality certifications, working capital, shareholder structure, energy and water reliability, and exposure to sanctions-related payment or supplier constraints. Dana can serve pharmaceutical distributors, buyers and partners seeking Iranian-made APIs and finished products across antibiotics, sterile preparations, injectables and oral dosage forms. Its integrated API and finished-product scope is relevant to sourcing and supply-chain relationships.
Constraints, risk & compliance
Key risks and constraints
Commercial performance is exposed to the operational demands of sterile and injectable manufacturing, product-quality requirements and the availability of inputs needed for API and finished-dose production.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around Dana Pharmaceutical Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does Dana Pharmaceutical Company manufacture?
Dana produces active pharmaceutical ingredients and finished medicines, including antibiotic products, injectable vials, capsules, tablets, oral suspensions, sterile drops, sterile water for injection and eye drops.
Where is Dana Pharmaceutical Company located?
The company is based in Tabriz, East Azerbaijan Province, Iran.
Is Dana Pharmaceutical Company publicly listed?
Yes. Dana Pharmaceutical Company is listed on Iran Fara Bourse under ticker ددانا (DDANA).
Why is Dana Pharmaceutical Company commercially relevant?
Its API and finished-dose manufacturing scope makes it relevant to pharmaceutical sourcing, antibiotic supply, sterile-product procurement and Iranian drug-sector investment analysis.